港股異動 | 特步國際盤中飆升16%,謝霆鋒再次認購特步國際500萬股
uSMART友信智投10月12日消息,週一港股早盤,特步國際盤中飆升16%,截至10:03分,特步國際漲14.34%,報2.87港元,創5個月高位。
中金唱好
中金發研報指,該行預計3季度特步零售銷售表現持續回升,其中2季度和1季度降幅分別爲低個位數和20-25%,維持目標價3.36港元不變。
謝霆鋒再次認購特步國際500萬股
特步國際10月9日披露公告,謝霆鋒已同意認購500萬股認購股份,認購價爲每股2.48港元,總價格爲1240萬港元,摺合人民幣約1070萬元。此前在2016年,謝霆鋒就曾以每股4.5港元的價格認購500萬股新股,佔已發行股份數目0.23%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.